Category: St. Jude Medical
The keys to a huge payoff in the medical device industry are cost-cutting technologies and those that target the right disease states, according to St. Jude CEO Daniel Starks.
MASSDEVICE ON CALL — The medical device industry has some pretty big hurdles to face, but companies can still land big wins if they can hit the market's "sweet spot", according to St. Jude Medical (NYSE:STJ) CEO Daniel Starks.
An FDA advisory panel votes that the CardioMEMS Champion device is safe and that its benefits outweigh its risks, but against its effectiveness.
Updated October 10, 2013, at 5 p.m. with comments from the CDRH panel.
Researchers compare battery life in active implanted defibrillators, reporting that Boston Scientific's devices have more durable batteries than implants from St. Jude Medical or Medtronic.
St. Jude Medical hits a new all-time high of $56.56 after analysts talk up the upcoming FDA meeting for St. Jude-backed CardioMEMs.
MassDevice.com looks at the internet chatter surrounding the medical device industry with some of most searched-for companies of the last month.
MassDevice.com looked at some of the most talked-about medical device companies, based on trends in U.S. Google searches for the last 30 days.
Nanosphere prices its offering of 15 million shares at $1.75 apiece, saying it aims raise more than $26 million for its molecular diagnostics technology.
Nanosphere (NSDQ:NSPH) said it priced a public offering of 15 million shares at $1.75 apiece, aiming to drum up a minimum of $26.3 million for its molecular diagnostics technology.
The family of Dr. Michel Mirowski, credited with inventing the implantable cardioverter defibrillator, takes Boston Scientific to court over alleged secret deal with St. Jude Medical.